Stryker Co. (NYSE:SYK) Shares Sold by New Mexico Educational Retirement Board

New Mexico Educational Retirement Board decreased its holdings in shares of Stryker Co. (NYSE:SYK) by 1.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 16,309 shares of the medical technology company’s stock after selling 300 shares during the period. New Mexico Educational Retirement Board’s holdings in Stryker were worth $5,872,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of SYK. Dunhill Financial LLC boosted its stake in shares of Stryker by 94.9% during the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock worth $27,000 after acquiring an additional 37 shares in the last quarter. Darwin Wealth Management LLC purchased a new stake in shares of Stryker during the 3rd quarter worth approximately $36,000. Activest Wealth Management purchased a new stake in shares of Stryker during the 4th quarter worth approximately $36,000. Crews Bank & Trust purchased a new stake in shares of Stryker during the 4th quarter worth approximately $39,000. Finally, Hara Capital LLC purchased a new stake in shares of Stryker during the 3rd quarter worth approximately $42,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Trading Down 0.9 %

SYK stock opened at $385.05 on Friday. The company has a market cap of $146.79 billion, a price-to-earnings ratio of 49.62, a PEG ratio of 2.98 and a beta of 0.96. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. The business has a fifty day simple moving average of $377.31 and a 200-day simple moving average of $366.30. Stryker Co. has a 52 week low of $314.93 and a 52 week high of $406.19.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period in the prior year, the company posted $3.46 earnings per share. On average, equities research analysts expect that Stryker Co. will post 13.49 EPS for the current year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be issued a $0.84 dividend. The ex-dividend date is Monday, March 31st. This represents a $3.36 annualized dividend and a yield of 0.87%. Stryker’s dividend payout ratio is currently 43.30%.

Analyst Upgrades and Downgrades

SYK has been the topic of several research analyst reports. JMP Securities reissued a “market perform” rating on shares of Stryker in a research note on Tuesday, January 7th. UBS Group upped their target price on Stryker from $366.00 to $370.00 and gave the company a “neutral” rating in a research note on Wednesday, October 30th. Royal Bank of Canada upped their target price on Stryker from $425.00 to $435.00 and gave the company an “outperform” rating in a research note on Wednesday, January 29th. The Goldman Sachs Group upped their target price on Stryker from $384.00 to $427.00 and gave the company a “neutral” rating in a research note on Thursday, January 30th. Finally, StockNews.com lowered Stryker from a “buy” rating to a “hold” rating in a research note on Thursday, January 30th. Five research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $420.68.

Insider Activity at Stryker

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of the company’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the transaction, the director now directly owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. This represents a 5.24 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 5.90% of the stock is owned by insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.